These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 25185168)

  • 1. Analysis finds value in pseudogenes.
    Cancer Discov; 2014 Sep; 4(9):978-9. PubMed ID: 25185168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Pan-Cancer analysis of pseudogene expression reveals biologically and clinically relevant tumour subtypes.
    Han L; Yuan Y; Zheng S; Yang Y; Li J; Edgerton ME; Diao L; Xu Y; Verhaak RGW; Liang H
    Nat Commun; 2014 Jul; 5():3963. PubMed ID: 24999802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pseudogene: promising signature for cancer reclassification : comment on "The Pan-Cancer analysis of pseudogene expression reveals biologically and clinically relevant tumour subtypes", Nat Commun. 2014; 5:3963.
    Lu XJ; Ji LJ
    Med Oncol; 2015 Jan; 32(1):354. PubMed ID: 25429833
    [No Abstract]   [Full Text] [Related]  

  • 4. Involvement of miRNAs and Pseudogenes in Cancer.
    Tutar L; Özgür A; Tutar Y
    Methods Mol Biol; 2018; 1699():45-66. PubMed ID: 29086367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of oncogenic genes by MicroRNAs and pseudogenes in human lung cancer.
    Tutar Y; Özgür A; Tutar E; Tutar L; Pulliero A; Izzotti A
    Biomed Pharmacother; 2016 Oct; 83():1182-1190. PubMed ID: 27551766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study.
    Takahashi K; Wang F; Kantarjian H; Doss D; Khanna K; Thompson E; Zhao L; Patel K; Neelapu S; Gumbs C; Bueso-Ramos C; DiNardo CD; Colla S; Ravandi F; Zhang J; Huang X; Wu X; Samaniego F; Garcia-Manero G; Futreal PA
    Lancet Oncol; 2017 Jan; 18(1):100-111. PubMed ID: 27923552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTTG3P promotes gastric tumour cell proliferation and invasion and is an indicator of poor prognosis.
    Weng W; Ni S; Wang Y; Xu M; Zhang Q; Yang Y; Wu Y; Xu Q; Qi P; Tan C; Huang D; Wei P; Huang Z; Ma Y; Zhang W; Sheng W; Du X
    J Cell Mol Med; 2017 Dec; 21(12):3360-3371. PubMed ID: 28631396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Third Joint Meeting on Lung Cancer of the FHU OncoAge (University Côte d'Azur, Nice, France) and the University of Texas MD Anderson Cancer Center (Houston, TX, USA). Understanding New Therapeutic Options and Promising Predictive Biomarkers for Lung Cancer Patients.
    Hofman P; Calin GA; Mani SA; Bontoux C; Ilié M; Wistuba II
    Cancers (Basel); 2022 Sep; 14(17):. PubMed ID: 36077862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Brief History of Thoracic Surgery at the University of Texas MD Anderson Cancer Center.
    Walsh GL; Mehran RJ
    Semin Thorac Cardiovasc Surg; 2016 Autumn; 28(3):719-726. PubMed ID: 28285679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polycystins: Mechanosensors with Diagnostic and Prognostic Potential in Cancer.
    Gargalionis AN; Papavassiliou KA; Basdra EK; Papavassiliou AG
    Trends Mol Med; 2016 Jan; 22(1):7-9. PubMed ID: 26700491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudogenes: newly discovered players in human cancer.
    Poliseno L
    Sci Signal; 2012 Sep; 5(242):re5. PubMed ID: 22990117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Commentary on: "Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial." Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR, CA184-043 Investigators. Departments of Urology and Immunology and Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN, USA, Electronic address: kwon.eugene@mayo.edu; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and Brady Urological Institute, Baltimore, MD, USA; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA; Institut Gustave Roussy, University of Paris-Sud, Villejuif, France; Institut Gustave Roussy, Villejuif, France; VU University Medical Centre, Amsterdam, Netherlands; Vienna General Hospital, Medical University Vienna, Vienna, Austria; Institut Bergonié, Bordeaux, France; CHU Caremeau, Nimes, France; Centro Médico Austral, Buenos Aires, Argentina; Centre Jean Perrin, Clermont-Ferrand, France; St John of God Hospital, Subiaco, WA, Australia; University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy; Hospital de Caridade de Ijuí, Ijuí, Brazil; Nottingham University Hospital, Nottingham, UK; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; Netherlands Cancer Institute and Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Institute of Oncology Ion Chiricuta and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania; Hospital Británico de Buenos Aires, Buenos Aires, Argentina; Herlev Hospital, Herlev, Denmark; Odense University Hospital, Odense, Denmark; University of Texas MD Anderson Cancer Center, Houston,
    Trump D
    Urol Oncol; 2016 May; 34(5):249-50. PubMed ID: 25907621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Markers in the Diagnosis and Treatment of Cancer.
    Gokden M; Ariza A; Arnaoutakis K
    Biomed Res Int; 2015; 2015():105217. PubMed ID: 26451364
    [No Abstract]   [Full Text] [Related]  

  • 14. HMGA1-pseudogenes and cancer.
    De Martino M; Forzati F; Arra C; Fusco A; Esposito F
    Oncotarget; 2016 May; 7(19):28724-35. PubMed ID: 26895108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The International Prognostic Index for Patients with Chronic Lymphocytic Leukemia Has the Higher Value in Predicting Overall Outcome Compared with the Barcelona-Brno Biomarkers Only Prognostic Model and the MD Anderson Cancer Center Prognostic Index.
    Muñoz-Novas C; Poza-Santaella M; González-Gascón Y Marín I; Hernández-Sánchez M; Rodríguez-Vicente AE; Infante MS; Heras C; Foncillas MÁ; Marín K; Hernández-Rivas JM; Hernández JÁ
    Biomed Res Int; 2018; 2018():9506979. PubMed ID: 29736400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNAs and neoplasia.
    Isin M; Dalay N
    Clin Chim Acta; 2015 Apr; 444():280-8. PubMed ID: 25748036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cancer stem cell markers and their prognostic value].
    Puchinskaya MV
    Arkh Patol; 2016; 78(2):47-54. PubMed ID: 27340717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abstracts of the 3rd EORTC-NCI International Meeting on Cancer Molecular Markers. April 18-20, 2004, Brussels, Belgium.
    Int J Biol Markers; 2004; 19 Suppl 3():S7-59. PubMed ID: 15129678
    [No Abstract]   [Full Text] [Related]  

  • 19. Automated analysis of immunohistochemistry images identifies candidate location biomarkers for cancers.
    Kumar A; Rao A; Bhavani S; Newberg JY; Murphy RF
    Proc Natl Acad Sci U S A; 2014 Dec; 111(51):18249-54. PubMed ID: 25489103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of potential cancer-related pseudogenes in lung adenocarcinoma based on ceRNA hypothesis.
    Wei Y; Chang Z; Wu C; Zhu Y; Li K; Xu Y
    Oncotarget; 2017 Aug; 8(35):59036-59047. PubMed ID: 28938616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.